NRSNW · NeuroSense Therapeutics Ltd.
Price & Indicators
The closing range uses available history since Aug 3, 2026; less than a full year is stored.
Latest filings
NeuroSense Therapeutics Ltd. signed an advisor collaboration to supply PrimeC through a licensed clinical treatment center, targeting first revenues in the first half of 2027, subject to legal, regulatory and operational requirements.
Read the 6-KTechnicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NRSNW
this stock
NeuroSense Therapeutics Ltd.
|
$4.50M | — | — | — | — |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.20B | +14.9% | +46.2% | 30.2 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.02B | +5.7% | +20.8% | 20.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.03B | +605.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 9.8%
- Reported
- 1 of 14
- Top holder
- UBS Group AG
- Filed
- Oct 26, 2026
- This year
- 32
NeuroSense Therapeutics Ltd. signed an advisor collaboration to supply PrimeC through a licensed clinical treatment center, targeting first revenues in the first half of 2027, subject to legal, regulatory and operational requirements.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NRSNW | -28.6% | -83.6% | — | -83.3% | — |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | -28.1% | -82.1% | — | -83.0% | — |